Creo Medical Group PLC (AIM:CREO) chief executive Craig Gulliford joined Proactive's Stephen Gunnion with details of a trading update, which forecasts sales for 2021 to beat expectations.
Gulliford attributed the rise in sales - to around £25 million from £9.4 million in 2020 - to significant growth in commercial orders and adoption of Speedboat Inject, which is used for flexible endoscopy.
He also flagged the successful acquisition of Aber Electronics, completed in November, and the signing of heads of terms with potential partners for its advanced energy technology.